Scholarlink

<p>Systemic sclerosis (SSc) and localised scleroderma (also known as morphoea) are two distinct autoimmune diseases that are both associated with skin sclerosis. Although there are pathogenic pathways common to both diseases, treatment of each differs substantially; thus, distinction between the two diseases is important. The high incidence of multiorgan involvement in SSc contributes to its morbidity and necessitates early systemic immunosuppressive intervention. Initial morphoea treatments are typically topical, such as corticosteroids or phototherapy, with systemic treatment reserved for severe cases. Various systemic therapies, including small molecule drugs and monoclonal antibodies, for SSc and morphoea are currently undergoing clinical investigation and some of the recent advances are summarised in this article.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Distinguish between systemic sclerosis and localised scleroderma (morphoea) to ensure appropriate treatment

  • 期刊论文

  • 发表日期：

    2025年7月14日

查看全文
  • Aisling McGuigan

摘要

Systemic sclerosis (SSc) and localised scleroderma (also known as morphoea) are two distinct autoimmune diseases that are both associated with skin sclerosis. Although there are pathogenic pathways common to both diseases, treatment of each differs substantially; thus, distinction between the two diseases is important. The high incidence of multiorgan involvement in SSc contributes to its morbidity and necessitates early systemic immunosuppressive intervention. Initial morphoea treatments are typically topical, such as corticosteroids or phototherapy, with systemic treatment reserved for severe cases. Various systemic therapies, including small molecule drugs and monoclonal antibodies, for SSc and morphoea are currently undergoing clinical investigation and some of the recent advances are summarised in this article.